Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus CapeOx perioperative therapy in locally advanced gastric and gastroesophageal junction adenocarcinoma
ChiCTR2100054502Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Pathological complete response rate (pCR). Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100054502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054502.